Koraújkortörténet = Early Modern History

A Koraújkortörténet című pályázat célkitűzése egy kora újkor történetét feldolgozó (tan)könyv kéziratának az "előállítása" volt. A kézirat elkészült. A szerződésben foglaltaknak megfelelően a kötet - 1,5-2 ív terjedelmű tanulmányokban - a 15-18. századi egyetemes történelem kulcskérdéseit taglalja négy tematikus blokkban: 1. Háborúk, polgárháborúk, forradalmak 2. Birodalmak, államok, tartományok 3. Vallásügy, vallási megújulás, vallásháborúk 4. Gyarmattartók és gyarmatok. A szerkesztett, de még kiadói szerkesztés előtt álló kéziratot mellékelem. Megjegyzések: 1. A beszámoló közlemények iránt érdeklődő rovatát azért nem töltöttem ki, mert a pályázat célja egy közlemény kéziratának az elkészítése volt, ami megtörtént. 2. A szerződésben vállaltam, hogy a kézirat elkészülte után kísérletet teszek a kötet megjelentetésére vagy - minimum - elektronikus formában hozzáférhetővé teszem. Bízom abban, hogy a Koraújkortörténet 2008-ban megjelenik. Ha nem, a 2008/9-es tanév első félévétől elérhető lesz az ELTE BTK honlapján. | The dedicated purpose of competition "Early-modern Ages" was to produce a volume focusing on the history of early-modern ages. The manuscript is finished. As set out in the contract the volume is composed of essays of 60-80.000 characters discussing key elements of 15th-18th century world history broken down to four areas of focus: 1. Wars, civil wars, revolutions; 2. Empires, states, provinces; 3. Religion, religious reform, wars of religion; 4. Colonizers and colonies. Find the copy-read manuscript submitted to editorial scrutiny attached. Notes: 1. I have not filled out the "publications" section of the report, since the purpose of the competition was the production of a manuscript for a publication. That is duely done. 2. In the contract I agreed to an attempt to publish a volume upon completing the manuscript or at least make it available online. I surely hope that "Early-modern Ages" will be published in 2008. If not, it will be available on the website of ELTE BTK as soon as 1st term of academic year 2008-2009

Decreased Expression ofZNF554in Gliomas is Associated with the Activation of Tumor Pathways and Shorter Patient Survival

Zinc finger protein 554 (ZNF554), a member of the Kruppel-associated box domain zinc finger protein subfamily, is predominantly expressed in the brain and placenta in humans. Recently, we unveiled that ZNF554 regulates trophoblast invasion during placentation and its decreased expression leads to the early pathogenesis of preeclampsia. Since ZNF proteins are immensely implicated in the development of several tumors including malignant tumors of the brain, here we explored the pathological role of ZNF554 in gliomas. We examined the expression of ZNF554 at mRNA and protein levels in normal brain and gliomas, and then we searched for genome-wide transcriptomic changes in U87 glioblastoma cells transiently overexpressingZNF554. Immunohistochemistry of brain tissues in our cohort (n= 62) and analysis of large TCGA RNA-Seq data (n= 687) of control, oligodendroglioma, and astrocytoma tissues both revealed decreased expression ofZNF554towards higher glioma grades. Furthermore, lowZNF554expression was associated with shorter survival of grade III and IV astrocytoma patients. Overexpression ofZNF554in U87 cells resulted in differential expression, mostly downregulation of 899 genes. The "PI3K-Akt signaling pathway", known to be activated during glioma development, was the most impacted among 116 dysregulated pathways. Most affected pathways were cancer-related and/or immune-related. Congruently, cell proliferation was decreased and cell cycle was arrested inZNF554-transfected glioma cells. These data collectively suggest that ZNF554 is a potential tumor suppressor and its decreased expression may lead to the loss of oncogene suppression, activation of tumor pathways, and shorter survival of patients with malignant glioma

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis.

BackgroundAtypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent recommendations suggest using it as a primary treatment for aHUS, important questions have arisen about the necessity of immediate use of eculizumab in all cases. We aimed to draw attention to a specific subgroup of aHUS patients with rapid disease progression and high mortality, in whom plasma therapy may not be feasible.MethodsWe present three pediatric patients of acute complement-mediated HUS with a fatal outcome. Classical and alternative complement pathway activity, levels of complement factors C3, C4, H, B and I, as well as of anti-factor H autoantibody and of ADAMTS13 activity were determined. The coding regions of CFH, CFI, CD46, THBD, CFB and C3 genes were sequenced and the copy number of CFI, CD46, CFH and related genes were analyzed.ResultsWe found severe activation and consumption of complement components in these patients, furthermore, in one patient we identified a previously not reported mutation in CFH (Ser722Stop), supporting the diagnosis of complement-mediated HUS. These patients were not responsive to the FFP therapy, and all cases had fatal outcome.ConclusionTaking the heterogeneity and the variable prognosis of atypical HUS into account, we suggest that the immediate use of eculizumab should be considered as first-line therapy in certain small children with complement dysregulation

The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children

Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an exclusion of other diseases Biologic agents are increasingly used on the side of disease-modifying anti-rheumatic drugs (DMARD) in JIA treatment.The aim of this meta-analysis was to investigate the observed infections in JIA children during tumor necrosis factor (TNF)-alpha inhibitor therapy. A systematic search of three databases (Medline via PubMed, Embase, Cochrane Library) was carried out up to May 2018. Published trials that evaluated the infectious adverse events in patients receiving TNF-alpha inhibitor vs. a control group were included in the analysis. Full-text data extraction was carried out independently by the investigators from ten relevant publications. 1434 patients received TNF-alpha inhibitor therapy; the control group consisted of 696 subjects. The analysis presented the risk of infection in the active treatment group (OR = 1.13; 95% CI: 0.76-1.69; p = 0.543). The majority of infections were upper respiratory tract infections (URTIs). Furthermore, the subgroup analysis demonstrated a higher infection rate in the observed localization.Anti-TNF therapy slightly but not significantly increases the incidence of infection in JIA children compared to other therapies (GRADE: moderate evidence). The most common infections reported were mild URTIs. Further studies with larger patients number with a strong evidence level are crucially needed to finalize the answer whether anti-TNF therapy elevates and if yes on what extent the incidence of infection in JIA children.Prospero: CRD42017067873